We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Chemomab Therapeutics Ltd | NASDAQ:CMMB | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 3.70% | 0.84 | 0.8001 | 1.07 | 0.845 | 0.7603 | 0.79 | 69,651 | 05:00:02 |
From Feb 2024 to May 2024
TEL AVIV, Israel, March 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor will deliver a corporate presentation and participate in investor meetings at the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida. Dr. Mor's presentation will be webcast live and will be available at the investor relations section of the Chemomab website for 90 days.
Leerink Partners Global BioPharma Conference
Date: | March 12, 2024 |
Time: | 10:40am ET |
Venue: | Fontainebleau Hotel |
Format: | Live presentation and webcast |
Webcast Link: | https://wsw.com/webcast/leerink33/cmmb/2189648 |
Information: | LeerinkEvents@Leerink.com |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-leerink-global-biopharma-conference-302079499.html
SOURCE Chemomab Therapeutics Ltd
Copyright 2024 PR Newswire
1 Year Chemomab Therapeutics Chart |
1 Month Chemomab Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
